These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 10359211)

  • 21. The capacity of the natural ligands for CD28 to drive IL-4 expression in naïve and antigen-primed CD4+ and CD8+ T cells.
    Bian Y; Hiraoka S; Tomura M; Zhou XY; Yashiro-Ohtani Y; Mori Y; Shimizu J; Ono S; Dunussi-Joannopoulos K; Wolf S; Fujiwara H
    Int Immunol; 2005 Jan; 17(1):73-83. PubMed ID: 15569772
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effective introduction of T cell costimulatory molecules into virus modified tumor cell vaccines by modification with bispecific antibodies.
    Haas C; Schirrmacher V
    Int J Oncol; 1997 Nov; 11(5):951-7. PubMed ID: 21528289
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells.
    Zhu M; Terasawa H; Gulley J; Panicali D; Arlen P; Schlom J; Tsang KY
    Cancer Res; 2001 May; 61(9):3725-34. PubMed ID: 11325845
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancer.
    Lamers CH; Willemsen RA; Luider BA; Debets R; Bolhuis RL
    Cancer Gene Ther; 2002 Jul; 9(7):613-23. PubMed ID: 12082462
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity.
    Giezeman-Smits KM; Okada H; Brissette-Storkus CS; Villa LA; Attanucci J; Lotze MT; Pollack IF; Bozik ME; Chambers WH
    Cancer Res; 2000 May; 60(9):2449-57. PubMed ID: 10811123
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
    Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
    Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vaccine therapy of established tumors in the absence of autoimmunity.
    Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
    Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autocrine costimulation: tumor-specific CD28-mediated costimulation of T cells by in situ production of a bifunctional B7-anti-CEA diabody fusion protein.
    Blanco B; Holliger P; Alvarez-Vallina L
    Cancer Gene Ther; 2002 Mar; 9(3):275-81. PubMed ID: 11896444
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential effect of sodium arsenite during the activation of human CD4+ and CD8+ T lymphocytes.
    Tenorio EP; Saavedra R
    Int Immunopharmacol; 2005 Dec; 5(13-14):1853-69. PubMed ID: 16275621
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of costimulatory molecules (CD80, CD86, CD28, CD152), accessory molecules (TCR alphabeta, TCR gammadelta) and T cell lineage molecules (CD4+, CD8+) in PBMC of leprosy patients using Mycobacterium leprae antigen (MLCWA) with murabutide and T cell peptide of Trat protein.
    Sridevi K; Neena K; Chitralekha KT; Arif AK; Tomar D; Rao DN
    Int Immunopharmacol; 2004 Jan; 4(1):1-14. PubMed ID: 14975355
    [TBL] [Abstract][Full Text] [Related]  

  • 31. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing.
    Chakraborty M; Abrams SI; Coleman CN; Camphausen K; Schlom J; Hodge JW
    Cancer Res; 2004 Jun; 64(12):4328-37. PubMed ID: 15205348
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nonantigen specific CD8+ T suppressor lymphocytes originate from CD8+CD28- T cells and inhibit both T-cell proliferation and CTL function.
    Filaci G; Fravega M; Negrini S; Procopio F; Fenoglio D; Rizzi M; Brenci S; Contini P; Olive D; Ghio M; Setti M; Accolla RS; Puppo F; Indiveri F
    Hum Immunol; 2004 Feb; 65(2):142-56. PubMed ID: 14969769
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A triad of costimulatory molecules synergize to amplify T-cell activation.
    Hodge JW; Sabzevari H; Yafal AG; Gritz L; Lorenz MG; Schlom J
    Cancer Res; 1999 Nov; 59(22):5800-7. PubMed ID: 10582702
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of CD4 T-cell responses to a tumor vaccine by cytokine flow cytometry.
    Maecker HT; Auffermann-Gretzinger S; Nomura LE; Liso A; Czerwinski DK; Levy R
    Clin Cancer Res; 2001 Mar; 7(3 Suppl):902s-908s. PubMed ID: 11300490
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
    Hao S; Yuan J; Xiang J
    J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimization studies for the coupling of bispecific antibodies to viral anchor molecules of a tumor vaccine.
    Fournier P; Aigner M; Schirrmacher V
    Int J Oncol; 2010 Nov; 37(5):1203-17. PubMed ID: 20878068
    [TBL] [Abstract][Full Text] [Related]  

  • 37. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro.
    Cao DY; Yang JY; Dou KF; Ma LY; Teng ZH
    Hum Immunol; 2007 May; 68(5):334-41. PubMed ID: 17462500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3.
    Scheffold C; Kornacker M; Scheffold YC; Contag CH; Negrin RS
    Cancer Res; 2002 Oct; 62(20):5785-91. PubMed ID: 12384539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD28, IL-2-independent costimulatory pathways for CD8 T lymphocyte activation.
    Sepulveda H; Cerwenka A; Morgan T; Dutton RW
    J Immunol; 1999 Aug; 163(3):1133-42. PubMed ID: 10415007
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
    Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.